Authors


Caroline Howard, PharmD, BCACP, CPP

Latest:

Population Health Management

Pharmacists play a vital role in chronic disease management.


Heather Morel, BS, MBA

Latest:

REMS Standards

Why are REMS not standardized today? Our columnist offers insight into the problem and how to lead specialty pharmacy forward.


Emma Yasinski

Latest:

Belief in Treatment Can Affect Patient Response to Pain Therapy

Chronic pain patient may respond to endogenous opioids differently than healthy people.


Rebecca A. Falter, PharmD

Latest:

Lipid Management When Converting Fluvastatin to Pravastatin: Medication Use Evaluation

There were no signifi cant differences in mean low-density lipoprotein cholesterol levels after patients were converted from fl uvastatin to pravastatin therapy.


Guido Zanni, PhD

Latest:

What Drives People to Overeat

Many different triggers prompt overeating, cues clinicians might use to a dieter's advantage.


Anne D. Martens, RN

Latest:

Psoriatric Arthritis: An Overview

Early diagnosis is the key to successful management of psoriatic arthritis, and treatment of this inflammatory disease is largely dependent on which symptoms are predominant.


Sarah N. Langford, PharmD candidate

Latest:

Nevada Addresses Costs for Diabetes Supplies

Manufacturers file challenge in court resulting in compromise between state government and pharmaceutical companies.



Amelia L. Persico MBA, PharmD

Latest:

Be Mindful of DDIs Between Analgesics and Oral Cancer Drugs

Although these chemotherapy agents provide convenience and ease, they are subject to hepatic first-pass metabolism and enzymatic drug-drug interactions.


Carisa D. Brewster

Latest:

Antacid Use During Pregnancy May Lead to Childhood Asthma

Up to 80% of women experience gastro-esophageal reflux disease during pregnancy.


Robert Kaminsky, MBA

Latest:

Hemophilia and Managed Care: Partnering to Achieve Cost-Effective Care

Exploring how health plans and hemophilia treatment centers can better work together to deliver high-quality care and manage costs associated with hemophilia.


Adriana Molodecki, PharmD Candidate

Latest:

Teaching Concentrations Add Value to Colleges of Pharmacy

Does your pharmacy institution offer students the opportunity to earn a concentration alongside their PharmD degree?


Rebecca Shanahan, Kelly Ratliff

Latest:

The Pharmaceutical Ecosystem Must Work Together to Provide Sustainable Innovation and Ensure Patient Access

Growth in the use of specialty drugs demands the evolution of patient care models that leverage the knowledge of all relevant stakeholders. 


James Radke, Rare Disease Report

Latest:

Famed Writer Dying of Liver Cancer

Writer and neurologist Oliver Sacks confirms he has terminal cancer of the liver.


Arthur L. Allen, PharmD

Latest:

Potentially Inappropriate Prescribing of Direct-acting Oral Anticoagulants in the Veterans Health Administration

This study examines variations in overall use, and potentially inappropriate use, of non-warfarin direct-acting oral anticoagulants across sites within the Veterans Health Administration.


Darcy Malard Johnson, PharmD

Latest:

Oncology Service Lines Prepare Pharmacy for Shift in Cancer Care Delivery

What can health systems do to provide a seamless journey during a time of uncertainty?


Chris Booth, PharmD

Latest:

Prevent Diversion During Drug Disposal

Building a team to support best practices, medication safety, and staff education will reduce risks.


Amish Patel

Latest:

Hemophilia Advancements and the Evolution of Patient Management

The coordinated-care models and high-touch services provided by specialty pharmacies put them in an ideal position to support patients with hemophilia now and in the future.


Alberto Coustasse, DRPh, MD, MBS, MPh

Latest:

503B: What Should Pharmacists Know for 2023?

When considering outsourcing, pharmacies should use a multistakeholder team to weigh pros and cons.


Nick C. Patel, PharmD, PhD, BCPP

Latest:

Understanding Predictors of Opioid Abuse: Predictive Model Development and Validation

This study developed and tested predictive models of opioid abuse using Humana commercial membership data that were subsequently tested in the Truven commercial data set.


Marc G. Sturgill, PharmD

Latest:

Irritable Bowel Syndrome: Helping Patients Access Appropriate Treatment in an Era of Investigation and Discovery

This Continuing Education activity is supported by an independent educational grant from Allergan Inc. and Prometheus Laboratories, Inc.


Winston Wong, PharmD

Latest:

The Pharmacist’s Role in Maximizing HIV Antiretroviral Therapy

Through ongoing quarterly targeted medication counseling follow-up sessions, the pharmacist may identify ART noncompliance.


Xiaolan Ye, PhD

Latest:

Real-World Immunoglobulin Dose Adjustments and Impact on Utilization and Costs

Real-world dose adjustments occurred in patients with primary immunodeficiency who switched from intravenous immunoglobulin to subcutaneous immunoglobulin 20%, with resulting implications for payers, patients, and plasma collection and supply.


Marile L. Santamarina, MS, PharmD

Latest:

ABCs of Avoiding Microvascular Comorbidities of Diabetes

Dr. Santamarina is an assistant professor of pharmacy practice at Palm Beach Atlantic University, Lloyd L. Gregory School of Pharmacy, West Palm Beach, Fla.


Miranda Wilhelm, PharmD

Latest:

Ensuring Health Equity in Vaccination Access: How Pharmacies Can Work With Community Organizations

Community pharmacies and organizations can collaborate to tailor strategies and interventions and address the challenges and specific needs of the community.



Sadaf Emad-Vaez, PharmD Candidate

Latest:

Use of Multiple Sclerosis Disease-Modifying Therapies During COVID-19 Pandemic

In the face of the COVID-19 pandemic, neurologists are concerned that immunosuppressive treatments for multiple sclerosis and other disorders have significant risks.




Alon Yehoshua, PharmD, MS

Latest:

Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions

This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.